Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...
As power density soars, air and single-phase loops hit their limits. A new webinar from Advanced Cooling technologies (ACT) shows how loop thermosyphons and pumped two-phase cooling unlock higher ...
The ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or IGA 0 or 1 Protagonist eligible to receive $115 million milestone ...
In the EMPOWER trials, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial. The most commonly reported adverse events in EMPOWER-1 and EMPOWER-2, ...
Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow cognitive and functional decline in persons with early Alzheimer’s disease. Gantenerumab is a subcutaneously administered ...
Monolithic boost converters can convert low input voltages to a higher output voltage, all in a compact solution size. However, when the output power requirements increase, so do current levels and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback